

Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following statements is true regarding outcomes of the Phase III DESTINY-Breast06 study evaluating trastuzumab deruxtecan (T-DXd) versus chemotherapy for patients with HR-positive, HER2-low and HER2-ultralow metastatic breast cancer (mBC) whose disease has progressed on endocrine therapy?
 - T-DXd did not demonstrate a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the intention-to-treat population
 - T-DXd demonstrated a trend toward significant and clinically meaningful improvement in PFS in the intention-to-treat population
 - T-DXd demonstrated a statistically significant and clinically meaningful improvement in PFS in the intention-to-treat population
- How is HER2-ultralow breast cancer defined?
 - HER2 immunohistochemistry (IHC) 1+ or 2+
 - HER2 IHC 1+
 - HER2 IHC 0 with $\leq 1\%$ staining
 - HER2 IHC 0 with $\leq 5\%$ staining
 - HER2 IHC 0 with $\leq 10\%$ staining
- Zenocutuzumab targets which of the following proteins?
 - HER2
 - HER3
 - Both a and b
 - 2 distinct HER2 domains
- What was the approximate response rate observed with zanidatamab in combination with evorpacept for patients with heavily treated HER2-positive advanced breast cancer after multiple HER2-targeted therapies, including T-DXd, in a Phase Ib/II trial?
 - 9%
 - 21%
 - 33%
 - 56%
- Which of the following statements best describes outcomes from the Phase III TROPiCS-02 trial evaluating sacituzumab govitecan for patients with HR-positive, HER2-negative mBC?
 - Sacituzumab govitecan demonstrated no apparent OS benefit
 - Sacituzumab govitecan demonstrated a numerical but nonsignificant improvement in OS
 - Sacituzumab govitecan demonstrated significant improvement in OS